Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM62E7C)

Drug Name
CPL-7075 Drug Info
Synonyms
Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo
Indication
Disease Entry ICD 11 Status REF
Diffuse systemic sclerosis 4A42.1 Phase 3 [1]
Cystic fibrosis CA25 Phase 2 [2]
Rheumatoid arthritis FA20 Phase 2 [3]
Systemic lupus erythematosus 4A40.0 Phase 2 [3]
Systemic sclerosis 4A42 Phase 2 [3]
Cross-matching ID
PubChem CID
3083542
ChEBI ID
CHEMBL456341
CAS Number
CAS 137945-48-3
TTD Drug ID
DM62E7C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tumor necrosis factor (TNF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [5]
Nafamostat DMU1XOD Pancreatitis DC31-DC34 Approved [6]
Pentoxifylline DMU3DNC Alcoholic hepatitis DB94.1 Approved [7]
Lenalidomide DM6Q7U4 Adult T-cell leukemia/lymphoma Approved [8]
Enbrel DM7RNP3 Arthritis FA20 Approved [9]
Golimumab DMHZV7X Psoriatic arthritis FA21 Approved [10]
Certolizumab DM5CL9Z Rheumatoid arthritis FA20 Approved [11]
Etanercept DMCV109 Arthritis FA20 Approved [12]
Adalimumab DMQMV1B Crohn disease DD70 Approved [13]
Infliximab DMH7OIA Crohn disease DD70 Approved [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Inhibitor [4]

References

1 ClinicalTrials.gov (NCT03398837) Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (RESOLVE-1). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
5 Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
8 Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
9 Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
10 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
11 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
12 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
13 Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
14 Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.